Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Askarian Amiri, Marjan E ^a   Seyfoddin, Vahid ^a   Smart, Chanel E ^b   Wang, Jingli ^a   Kim, Ji Eun ^a,c   Hansji, Herah ^a   Baguley, Bruce C ^a   Finlay, Graeme J ^a   Leung, Euphemia Y ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LONG UNTRANSLATED RNA; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX;

ADULT STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CELL ANCHORAGE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; SOX2 GENE; SOX2OT GENE; UPREGULATION; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CELL DIFFERENTIATION; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASTIC STEM CELLS; RNA, LONG NONCODING; SOXB1 TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84903974262     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102140     Document Type: Article

References (59)

1. Bowles J, Schepers G, Koopman P (2000) Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 227: 239-255.
2. Wilson M, Koopman P (2002) Matching SOX: partner proteins and co-factors of the SOX family of transcriptional regulators. Curr Opinion Genet Dev 12: 441-446. (Pubitemid 34722924)
3. Kamachi Y, Uchikawa M, Kondoh H (2000) Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 16: 182-187. (Pubitemid 30169154)
4. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676. (Pubitemid 44233629)
5. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, et al. (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26: 101-106.
6. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. (2008) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26: 1269-1275.
7. Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448: 313-317. (Pubitemid 47080336)
8. Alonso M, Diez-Valle R, Manterola L, Rubio A, Liu D, et al. (2011) Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6: e26740.
9. Basu-Roy U, Seo E, Ramanathapuram L, Rapp T, Perry J, et al. (2012) Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 31: 2270-2282.
10. Chen Y, Shi L, Zhang L, Li R, Liang J, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17978.
11. Cox J, Wilder P, Desler M, Rizzino A (2012) Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One 7: e44087.
12. Girouard S, Laga AC, Mihm MC, Scolyer RA, Thompson JF, et al. (2012) SOX2 contributes to melanoma cell invasion. Lab Invest 92: 362-370.
13. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, et al. (2011) Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene.
14. Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V, et al. (2011) Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 11: 42.
15. Li X, Eishi Y, Bai YQ, Sakai H, Akiyama Y, et al. (2004) Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 24: 257-263.
16. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, et al. (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32: 164-170.
17. Sattler H, Lensch R, Rohde V, Zimmer E, Meese E, et al. (2000) Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 45: 207-215.
18. Seo E, Basu-Roy U, Zavadil J, Basilico C, Mansukhani A (2011) Distinct functions of Sox2 control self-renewal and differentiation in the osteoblast lineage. Mol Cell Biol 31: 4593-4608.
19. Simoes B, Piva M, Iriondo O, Comaills V, Lopez-Ruiz JA, et al. (2011) Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat 129: 23-35.
20. Wu F, Zhang J, Wang P, Ye X, Jung K, et al. (2012) Identification of two novel phenotypically distinct breast cancer cell subsets based on Sox2 transcription activity. Cell Signal 24: 1989-1998.
21. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genet 40: 499-507. (Pubitemid 351601215)
22. Rodriguez-Pinilla S, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez M, et al. (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20: 474-481. (Pubitemid 46482371)
23. Chen L, Xiao Z, Meng Y, Zhao Y, Han J, et al. (2012) The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 33: 1437-1444.
24. Dontu G, Abdallah W, Foley J, Jackson K, Clarke M, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270. (Pubitemid 36583168)
25. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, et al. (2012) Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31: 1354-1365.
26. Miyagi S, Saito T, Mizutani K, Masuyama N, Gotoh Y, et al. (2004) The Sox-2 regulatory regions display their activities in two distinct types of multipotent stem cells. Mol Cell Biol 24: 4207-4220. (Pubitemid 41070994)
27. Kondo T, Raff M (2004) Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 18: 2963-2972. (Pubitemid 39602314)
28. Tomioka M, Nishimoto M, Miyagi S, Katayanagi T, Fukui N, et al. (2002) Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 30: 3202-3213. (Pubitemid 34846184)
29. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, et al. (2007) RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316: 1484-1488. (Pubitemid 46906616)
30. Lander E, Linton L, Birren B, Nusbaum C, Zody M, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921.
31. Venter J, Adams M, Myers E, Li P, Mural R, et al. (2001) The sequence of the human genome. Science 291: 1304-1351. (Pubitemid 32173090)
32. Carninci P (2007) Constructing the landscape of the mammalian transcriptome. J Exp Biol 210: 1497-1506.
33. Mercer T, Dinger ME, Mattick JS. (2009) Long non-coding RNAs: Insights into functions. Nat Rev Genet 10: 155-159.
34. Pang K, Frith M, Mattick J (2006) Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet 22: 1-5. (Pubitemid 43011990)
35. Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JR, et al. (2003) Mutations in SOX2 cause anophthalmia. Nat Genet 33: 461-463. (Pubitemid 36390005)
36. Amaral P, Neyt C, Wilkins SJ, Askarian-Amiri ME, Sunkin SM, et al. (2009) Complex architecture and regulated expression of the Sox2ot locus during vertebrate development. RNA 15: 2013-2027.
37. Shahryari A, Rafiee M, Fouani Y, Oliae N, Samaei N, et al. (2014) Two Novel Splice Variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are Coupregulated with SOX2 and OCT4 in Esophageal Squamous Cell Carcinoma. Stem Cells 32: 126-134.
38. Smart C, Morrison B, Saunus J, Vargas A, Keith P, et al. (2013) In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity. PLoS One 8: e64388.
39. Leung E, Kannan N, Krissansen G, Findlay M, Baguley B (2010) MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9: 717-724.
40. Jenkins D, Hornig Y, Oei Y, Dusich J, Purchio T (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7: R444-454.
41. Askarian-Amiri ME, Crawford J, French JD, Smith MA, Smart CE, et al. (2011) SNORD-host RNA Znfx1-as is a regulator of mammary development and a potential marker for breast cancer. RNA 17: 878-891.
42. Leung E, Kim J, Rewcastle G, Finlay G, Baguley B (2011) Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther 11: 938-946.
43. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116.
44. Nielsen M, Tehler D, Vang S, Sudzina F, Hedegaard J, et al. (2014) Identification of expressed and conserved human noncoding RNAs. RNA 20: 236-251.
45. Piva M, Domenici G, Iriondo O, Rabano M, Simoes B, et al. (2014) Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 6: 66-79.
46. Cariati M, Naderi A, Brown J, Smalley M, Pinder S, et al. (2008) Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122: 298-304. (Pubitemid 350234715)
47. Fillmore C, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
48. Grimshaw M, Cooper L, Papazisis K, Coleman J, Bohnenkamp H, et al. (2008) Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 10: R52.
49. Wilson M, Koopman P (2002) Matching SOX: partner proteins and co-factors of the SOX family of transcriptional regulators. Curr Opin in Genet Dev 12: 441-446. (Pubitemid 34722924)
50. Comtesse N, Zippel A, Walle S, Monz D, Backes C, et al. (2005) Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad of Sci U S A 102: 9601-9606. (Pubitemid 40981727)
51. Gure A, Stockert E, Scanlan M, Keresztes R, Jager D, et al. (2000) Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A 97: 4198-4203. (Pubitemid 30226110)
52. Boer B, Kopp J, Mallanna S, Desler M, Chakravarthy H, et al. (2007) Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res 35: 1773-1786. (Pubitemid 47061649)
53. Baguley B, Leung E (2011) Heterogeneity of phenotype in breast cancer cell lines. In: Gunduz M, editor. Breast Cancer Cells - carcinogenesis, cell Growth and signaling pathways: Intech Publishers. pp. 245-256.
54. Leung E, Baguley B (2014) mTOR signaling in endocrine resistance growth control. The Research and Biology of Cancer. In: Fung G, editor. Breast, Cervical and Prostate Cancer: iConcept Press Ltd. pp. In press.
55. Leung E, Hung JM, Barker D, Reynisson J (2014) The effect of a thieno[2,3-b] pyridine PLC-gamma inhibitor on the proliferation, morphology, migration and cell cycle of breast cancer cells. MedChemComm 5: 99-106.
56. Leung E, Kim JE, Askarian-Amiri M, Finlay GJ, Baguley BC (2014) Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population. Biomed Res Int 2014: 836769.
57. Leung E, Rewcastle GW, Joseph WR, Rosengren RJ, Larsen L, et al. (2012) Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Inves New Drugs 30: 2103-2112.
58. Corominas-Faja B, Cufi S, Oliveras-Ferraros C, Cuyas E, Lopez-Bonet E, et al. (2013) Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle 12: 3109-3124.
59. Zhou J, Su P, Wang L, Chen J, Zimmermann M, et al. (2009) mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc Natl Acad Sci U S A 106: 7840-7845.